Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Blind, Parallel Controlled, Single Dose Pharmacokinetic Study of Recombinant Humanized Anti-HER-2 Monoclonal Antibody Injection GB221 in Comparison With Herceptin ® in Chinese Healthy Adult Volunteers

NCT04905667 is registered in ClinicalTrials.gov with Genor Biopharma Co., Ltd. as lead sponsor.

NCT NCT04905667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04905667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Blind, Parallel Controlled, Single Dose Pharmacokinetic Study of Recombinant Humanized Anti-HER-2 Monoclonal Antibody Injection GB221 in Comparison With Herceptin ® in Chinese Healthy Adult Volunteers
Lead sponsor
Genor Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 13, 2019
Completion date
September 11, 2020
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer